Data from participants with treatment-resistant depression is revolutionizing our understanding of network disorders 🧠💻 Listen to a great discussion between Christopher Rozell and Paul Middlebrooks on the potential of neuromodulation as a treatment for psychiatric disorders 🎙️

What I’m reading 👉📚 A powerful & personal piece by Jacob Robinson (CEO motif neurotech) on how brain-computer interfaces (#BCIs) could transform mental health. Honest, bold & inspiring. I encourage folks to read & subscribe. brainjacob.substack.com

I left this year’s One Mind music festival feeling truly inspired by the advances in mental health research & awareness that, together, are cracking the future of care wide open. Proud to be part of this community alongside peers like Maryam Shanechi & Lugo Lab!

Excited to be speaking at #NYBCI25 this weekend, alongside so many leaders in #Neurotech and #BCI. It’s rare to have such diverse perspectives in one place, and I’m looking forward to the dialogue that emerges from bringing them together to advance the field. See you there!

"It takes a village!" and I'm incredibly grateful to be a part of this one. It’s inspiring to witness the growing community driving cutting-edge #BCI research from the bench to real life at #NYBCI25. Thanks to @mountsinaineuro and all attendees for a great event 🧠

What does it take to move neuroengineering breakthroughs into real-world impact? Our workshop at IEEE Engineering Medicine and Biology Society #NER25 hosted by One Mind Accelerator, will explore how research, startups, and investment can come together to advance mental health care. Learn more: neuro.embs.org/2025/satellite…

Must-read #NYBCI25 coverage by Naveen Rao in Forbes. My key takeaway on cognitive BCI: Our biggest limiting factor isn't tech—it's fundamental scientific understanding. We can’t advance the tech until we define the disorder. Basic research must lead the way!

BD² has awarded $18M to four new Discovery Research teams to study neuromodulation and brain circuits in #BipolarDisorder. 🔗Learn more: bit.ly/48M1TKP Hear from Daniel Pham, PhD, Program Director, and the new teams on what their projects entail 👇

How mood states shift in the brain remains one of psychiatry’s biggest mysteries. With generous support from BD², our Friedman Brain Institute team will apply cutting-edge techniques to map these transitions—aiming to build the most precise understanding of bipolar disorder yet.

What does "Human-centered neural engineering and AI" mean? It means prioritizing the patient across the entire pipeline: Discovery, Design, and Delivery of neuro-engineering treatments for psychiatric disorders. Join me to discuss at IEEE Engineering Medicine and Biology Society #NER25 hosted by One Mind Accelerator

✨ Program Manager Job Alert✨ Join our Mount Sinai team to steer a multi-institutional neuroscience initiative aimed at understanding Bipolar Disorder. If you’re passionate about science, data & impact we’d love to hear from you! Learn More & Apply 👇 careers.mountsinai.org/jobs/3032351?l…

Congratulations to Eric J. Nestler, MD, PhD, MD, PhD on his appointment as the Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai! In his new role as Dean, he will help guide one of the nation’s leading medical schools into its next era of innovation, education and discovery. Dr. Nestler is

Feeling immense gratitude for my scientific community this season 🙏 Huge thanks to @OneMindorg & BD² for making ambitious research possible, Icahn School of Medicine at Mount Sinai @sinaibrain leadership for their support, & to our incredible BD2 team! Looking forward to the work ahead!

BD² Grantee Research Spotlight🚨: Ignacio Saez, PhD of Icahn School of Medicine at Mount Sinai will study brain activity in people with #BipolarDisorder during manic & depressive shifts. Goal: Identify patterns that could guide new treatments using targeted brain stimulation. 🔗 bit.ly/4gTbBwU